Cancer Diagnostics Market Summary
The global cancer diagnostics market size was valued at USD 28.6 billion in 2025 and is projected to reach USD 31.2 billion in 2026 to USD 58.7 billion by 2033, at a CAGR of 9.5% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.5% in 2025. Market growth is driven by the increasing global cancer burden, expansion of population-based screening programs, rising demand for early and accurate diagnosis, and growing adoption of molecular diagnostics, next-generation sequencing, liquid biopsy, and advanced imaging technologies.
Global Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global cancer diagnostics market report on the basis of product, type, indication, test type, end use, and region.
- Product Outlook (Revenue, USD Billion, 2021 - 2033)
- Instruments
- Pathology-based Instruments
- Slide Staining Systems
- Tissue Processing Systems
- Cell Processors
- PCR Instruments
- NGS Instruments
- Microarrays
- Other Pathology-based Instruments
- Imaging Instruments
- Others
- Consumables
- Antibodies
- Kits & reagents
- Probes
- Others
- Services
- Type Outlook (Revenue, USD Billion, 2021 - 2033)
- IVD
- By Type
- Diagnosis
- Early Detection
- Therapy Selection
- Monitoring
- By Technology
- Polymerase Chain Reaction (PCR)
- In Situ Hybridization (ISH)
- Immunohistochemistry (IHC)
- Next-generation Sequencing (NGS)
- Microarrays
- Flow Cytometry
- Immunoassays
- Other IVD Testing Technologies
- LDT
- Imaging
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- Positron Emission Tomography (PET)
- Mammography
- Ultrasound
- Others
- Indication Outlook (Revenue, USD Billion, 2021 - 2033)
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Lung Cancer
- Prostate Cancer
- Skin Cancer
- Blood Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Others
- End use Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospitals
- Laboratories
- Others
- Test Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Biopsy
- Fine-needle Aspiration
- Core Biopsy
- Surgical Biopsy
- Skin Biopsy /Punch Biopsy
- Others
- Others
- Regional Outlook (Revenue, USD Million; 2021 - 2033)
- North America
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Norway
- Denmark
- Sweden
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait